Fragile X syndrome is an X-linked inherited mental disorder, caused by a mutation in the FMR1 gene. 20% of the general population with an intelligence quotient (IQ) below what is considered normal has an x-linked mental retardation. Prevalence of this syndrome in the general Caucasian population is approximately 1 in 4000 for males and 1 in 8000 for females.
Fragile X syndrome is an X-linked inherited mental disorder, caused by a mutation in the FMR1 gene. 20% of the general population with an intelligence quotient (IQ) below what is considered normal has an x-linked mental retardation. Prevalence of this syndrome in the general Caucasian population is approximately 1 in 4000 for males and 1 in 8000 for females.
Fragile X syndrome is an X-linked inherited mental disorder, caused by a mutation in the FMR1 gene. 20% of the general population with an intelligence quotient (IQ) below what is considered normal has an x-linked mental retardation. Prevalence of this syndrome in the general Caucasian population is approximately 1 in 4000 for males and 1 in 8000 for females.
The fragile X syndrome and its main characteristics
Fragile X syndrome (FXS) is an X-linked inherited mental disorder, caused by a mutation in the FMR1 gene. The FXS is the most common form of inherited mental retardation in humans. It is believed that 20% of the general population with an intelligence quotient (IQ) below what is considered normal (IQ < 70) has an X-linked mental retardation, between those, the locus responsible for the fragile X syndrome shares the largest amount (GARBER, K. B. et. al., 2008; PENAGARIKANO, O. et. al., 2007). The first description of X-linked mental retardation came in 1943 by Martin and Bell. In 1969 Herbert Lubs developed a chromosomal test for the unusual constrictions in the end of the long arms of the X chromosome that he found in 7 individuals of the same family. Sometime later, the so called Martin-Bell syndrome or marker X syndrome, became known as fragile X syndrome, after Richards and Sutherland analyzed and associated the descriptions from Martin-Bell and Lubs with FXS (PENAGARIKANO, O. et. al., 2007). The prevalence of this syndrome in the general Caucasian population is approximately 1 in 4000 for males and 1 in 8000 for females, for other populations little is known about the prevalence or the incidence of FXS. In one population-based study for non-Caucasians, the result for African-Caribbean and African- American populations showed a higher estimate point than in Caucasians, such as 1 in 2500 for the general population, but further studies are needed to investigate this results (CRAWFORD, D. C. et. al., 2001). The primarily characteristics and clinical indications of FXS is often slow developmental hallmarks, such as mild motor and language, autistic-like behaviors, low IQ and some common observable features such as prominent ears and fore-heads, long narrow faces and long palpebral fissures. In general, the mental deficits include short-term memory problems, logical and visuospatial inabilities. Since it is an X-linked disorder, females are much less affected than males, mostly in terms of cognitive ability. Full-mutation females often shows a normal IQ (GARBER, K. B. et. al., 2008). The mutation that leads to FXS is a CGG polymorphic repeat at the 5 untranslated region (UTR) of the FMR1 gene, located at Xq27.3. The repeat expansion length of CGG determines the how the individual is affected. Normal individuals have 6 to 54 polymorphic copies, female carriers and normal transmitting males (NTMs) bears 55 to 200 repeats (categorized as a pre- mutation) and when the expansion is larger than 200 repeats, it is considered as a full-mutation and the individual might present features of mental retardation and other phenotype characteristics. The mutation is passed between generations, were a NTM does not transmit the gene to his male offspring but to his female daughter, and the mother can transmit both to his son or daughter, and the mutation might be given with expansion, increasing exponentially according to the number of repeats from the mothers allele. Full-mutation expansion only occurs when transmitted by a female carrier, once the full-mutation males only carries pre-mutation alleles in their sperm. When carrying the full-mutation, the gene sequence becomes abnormally methylated and the gene is silenced. The absence of the FMR1 gene protein must be the cause of the mental retardation, since it is a single gene based syndrome (JIN, P.; WARREN, S. T., 2000; PENAGARIKANO, O. et. al., 2007; SHERMAN, S. et. al., 2008). To understand how the FMRP causes mental retardation, this protein has been extensively studied in the past several years. The main phenotype of fragile X syndrome, mental retardation, is in the Central Nervous System (CNS), the question is: What is the function of FMRP is in CNS, and how its absence leads to mental deficit? Based on the findings from the last decade, it has been speculate that FMRP plays a role in the transportation of mRNAs from nucleus to cytoplasm in neurons (crucially in dendrites), and also regulates the protein synthesis at that local, by being part of polyribosome complexes. The regulation of protein synthesis in the dendrites allows synaptic development and plasticity, seeing that synaptic plasticity is essential for promotion of memory and learning processes, the last observations on the physiological role of FMRP explains how the mutation generates the syndrome (penagakioke Crawford, outros). The molecular mechanism for the trinucleotide repeat expansion is still unclear. It is believed that this phenomenon is likely due to a mechanism of slipping-strand mispairing during DNA replication in the Okazaki fragments (PENAGARIKANO, O. et. al., 2007).
REFERENCES
Crawford, D. C. et. al. FMR1 and the fragile syndrome: Human genome epidemiology review. Genetics in Medicine. Vol. 3, n. 5, pg. 359-371, 2001. Garber, K. B. et. al. Fragile X syndrome. Nature and European Journal of Human Genetics. N. 16, pg. 666-672, 2008. Jin, P.; Warren, S. T. Understanding the molecular basis of fragile X syndrome. Human Molecular Genetics. Vol. 9, n. 6, pg. 901-908, 2000. Penagarikano, O. et. al. The pathophysiology of Fragile X Syndrome. Annual Review of Genomics and Human Genetics. N. 8, pg. 109-129, 2007. Sherman, S. et. al. Fragile X syndrome: Diagnostic and carrier testing. Genetics in Medicine. Vol. 7, n. 8, pg. 584-587, 2008.